All patients with adenocarcinoma had at least immunochemistry analysis to assess for Anaplastic lymphoma kinase (EML4/ALK) rearrangement and real-time Polymerase Chain Reaction (PCR) assay with high resolution melting (HRM) to assess mutation on Epidermal Growth Factor Receptor (EGFR), V-Raf murine sarcoma viral oncogene homolog B (BRAF), and V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS). This evidence concerns the gene KRAS and adenocarcinoma.